Stocks · Healthcare · Drug Manufacturers - Specialty & Generic
Collegium Pharmaceutical, Inc. COLL
$22.02 +0.82% Close, Oct 2, 2026 · NASDAQ · Market cap $714.2M
High qualityWeak trendInexpensive vs sector
Next earnings report: Nov 5, 2026
Scroll or pinch to zoom, drag to move. Daily prices adjusted for splits. Markers: E = earnings (green beat, red miss), S = split, D = dividend.
Three things to know
- The diluted share count fell 16.9% in a year, mainly through buybacks.
- The stock is 56% below its highest close of the past year.
- The stock is in a downtrend: below its 200-day average, with the 50-day average below the 200-day.
PromtFinance scores
Each score is a percentile within the Healthcare sector (0–100). Under each score: how the stock ranks in its sector on every component. As of Oct 5, 2026.
How fast revenue, earnings and cash flow are growing.
- Revenue growth (TTM, YoY)Top 41%
- EPS growth (TTM, YoY)Top 41%
- FCF growth (TTM, YoY)Top 24%
- Revenue growth, 3-year CAGRTop 32%
- Revenue growth accelerationBottom 24%
Returns on capital, margins, earnings quality and balance-sheet strength.
- Return on invested capitalTop 22%
- Gross marginBottom 45%
- Operating marginTop 13%
- Cash conversion (OCF / net income)Top 10%
- Accruals (lower is better)Top 25%
- Net debt / EBITDA (lower is better)Bottom 49%
- Interest coverTop 41%
How cheap the shares are relative to earnings, cash flow and their own history.
- Earnings yieldTop 8%
- Free-cash-flow yieldTop 1%
- EBITDA / enterprise valueTop 2%
- Sales / enterprise valueTop 22%
- P/E vs own 5-year history (lower is better)Bottom 44%
Strength and persistence of the price trend, including versus the S&P 500.
- 12-month return excluding last monthBottom 16%
- 6-month returnBottom 14%
- 1-year return vs S&P 500Bottom 17%
- Distance from 52-week highBottom 20%
- Trend checklist (0–4)Bottom 14%
Earnings surprises and analyst sentiment (estimate-revision history is being collected).
- Average EPS surprise, last 4 quartersTop 36%
- Consecutive EPS beatsTop 35%
- Share of analysts rating BuyBottom 34%
- Upside to consensus price targetTop 33%
Low volatility, shallow drawdowns, low market sensitivity and modest leverage.
- Volatility, 60 days (lower is better)Bottom 49%
- Maximum drawdown, 3 yearsTop 30%
- Beta vs S&P 500 (lower is better)Top 11%
- Net debt / EBITDA (lower is better)Bottom 49%
What changed
Latest four quarters versus the same period a year earlier (growth: versus one quarter earlier).
| Measure | Before | Now | |
|---|---|---|---|
| Revenue growth (YoY) | 19.9% | 14.3% | ↓ |
| EPS growth (YoY) | 68.1% | 20.0% | ↓ |
| Gross margin | 56.7% | 60.0% | ↑ |
| Operating margin | 18.4% | 19.6% | ↑ |
| FCF margin | 28.5% | 40.6% | ↑ |
Fundamental momentum
| Measure | Now (TTM) | Year / quarter before | Sector rank | |
|---|---|---|---|---|
| Revenue growth (TTM, YoY) | 14.3% | 19.9% | ↓ | Top 41% |
| EPS growth (TTM, YoY) | 20.0% | 68.1% | ↓ | Top 41% |
| Gross margin | 60.0% | 56.7% | ↑ | Bottom 45% |
| Operating margin | 19.6% | 18.4% | ↑ | Top 13% |
| Net margin | 5.9% | 5.1% | ↑ | — |
| Free-cash-flow margin | 40.6% | 28.5% | ↑ | — |
| Return on invested capital | 6.1% | — | Top 22% | |
| Revenue growth, 3-year CAGR | 18.9% | — | Top 32% |
Quality of earnings and balance sheet
- Cash conversion (OCF / net income)Above 1× means profits are backed by cash.
- 3.00×
- Accruals (net income − OCF) / assetsLower is better; high accruals can signal weaker earnings quality.
- -13.2%
- Stock-based compensation / revenueA cost to shareholders through dilution.
- 5.6%
- Receivables growth vs revenue growthReceivables growing much faster than sales can be a warning.
- +19.5 pp
- Net debt / EBITDABelow 1× is conservative; above 3× is high leverage.
- 1.24×
- Interest cover (operating income / interest)How many times operating profit covers interest.
- 1.0×
Shareholder returns
- Dividend yield (dividends paid, TTM)
- 0.00%
- Net buyback yield (TTM)
- -0.71%
- Shareholder yield
- -0.71%
- Share count change, 1 year
- -16.9%
- Share count change, 3-year CAGR
- -8.8%
Shareholder yield = dividends + net buybacks over the last four quarters, divided by market cap.
Based on the four quarters through Jun 30, 2026 (filed Aug 6, 2026).
Earnings and expectations
Earnings momentum
- Consecutive EPS beats
- 2
- Beats in the last 8 reports
- 7 of 8
- Average EPS surprise, last 4
- +10.9%
- Average 2-day reaction, last 8
- +1.5%
- Positive 20 days after report
- 4 of 8
Analysts
- Consensus price target
- $48.00
- Target vs current price
- +118.0%
- Analysts with a rating
- 12
- Share rating Buy or Strong Buy
- 67%
- Consensus rating
- Buy
How the stock reacted to recent reports
| Report date | EPS surprise | 2 days | 5 days | 20 days | 60 days |
|---|---|---|---|---|---|
| Aug 6, 2026 | +11.6% | -18.6% | -28.1% | -32.0% | — |
| May 7, 2026 | +15.8% | +7.7% | -4.5% | -10.5% | -2.5% |
| Feb 26, 2026 | -4.7% | -3.3% | -13.4% | -27.3% | -24.8% |
| Nov 6, 2025 | +21.0% | +13.4% | +32.1% | +32.3% | +32.5% |
| Aug 7, 2025 | +3.7% | +10.7% | +27.3% | +31.9% | +19.8% |
| May 8, 2025 | +4.2% | +0.8% | +7.5% | +9.1% | +14.9% |
| Feb 27, 2025 | +14.9% | +0.2% | +0.4% | +5.7% | +1.7% |
| Nov 7, 2024 | +1.3% | +0.6% | -12.5% | -13.4% | -11.0% |
Returns from the close before each report. Past reactions do not determine future ones.
Earnings history
| Report date | EPS | Estimate | Surprise | Revenue |
|---|---|---|---|---|
| Aug 6, 2026 | $1.92 | $1.72 | +11.6% | $199.9M |
| May 7, 2026 | $1.76 | $1.52 | +15.8% | $193.5M |
| Feb 26, 2026 | $2.04 | $2.14 | -4.7% | $205.4M |
| Nov 6, 2025 | $2.25 | $1.86 | +21.0% | $209.4M |
| Aug 7, 2025 | $1.68 | $1.62 | +3.7% | $188.0M |
| May 8, 2025 | $1.49 | $1.43 | +4.2% | $177.8M |
| Feb 27, 2025 | $1.77 | $1.54 | +14.9% | $181.9M |
| Nov 7, 2024 | $1.61 | $1.59 | +1.3% | $159.3M |
Valuation in context
| Multiple | Now | 5-year median | 5-year percentile | Sector rank (cheapness) |
|---|---|---|---|---|
| P/E (trailing) | 17.8× | 17.8× | 50th | Top 8% |
| P/E (forward) | 3.0× | — | — | — |
| EV / EBITDA | 2.5× | — | — | Top 2% |
| EV / Sales | 1.78× | — | — | Top 22% |
| Free-cash-flow yield | 45.97% | — | — | Top 1% |
| Earnings yield | 5.63% | — | — | Top 8% |
P/E over the past five years
Range 7.4× – 144.5× since Jun 30, 2021. Each point: price on the filing date divided by trailing-twelve-month EPS known then.
What moved the stock over the past year
- Price return, 1 year
- -37.4%
- Earnings per share growth (TTM)
- +20.0%
- Change in P/E multiple
- -26.3%
Most of the move came from a change in the valuation multiple.
Technical state
Trend checklist
- ✗ Price above 20-day average
- ✗ Price above 50-day average
- ✗ Price above 200-day average
- ✗ 50-day average above 200-day
- ✓ MACD histogram positive
Trend quality
- Days above the 50-day average
- 0
- Days above the 200-day average
- 0
- 50-day average slope (20 days)
- -16.6%
- 200-day average slope (20 days)
- -6.3%
- Distance from 50-day average
- -17.7%
- Distance from 200-day average
- -38.4%
- RSI (14)
- 30.9
- Relative volume
- 0.75×
Risk and drawdowns
- Volatility, 60 days (annualized)
- 56.0%
- Volatility vs own 5-year history
- 97th percentile · High for this stock
- Beta vs S&P 500 (2 years, weekly)
- 0.36
- Correlation with S&P 500
- 0.14
- Current drawdown from 1-year high
- -55.8%
- Maximum drawdown, 3 years
- -56.2%
Largest declines in the past six years
| From peak | To low | Decline | Length | Recovery |
|---|---|---|---|---|
| Dec 26, 2025 | Sep 30, 2026 | -56.2% | 190 days | Not yet recovered |
| Feb 24, 2021 | May 9, 2022 | -45.5% | 304 days | 165 days (Jan 4, 2023) |
| Oct 4, 2024 | Apr 10, 2025 | -41.1% | 128 days | 146 days (Nov 7, 2025) |
| Feb 2, 2023 | Jun 5, 2023 | -29.5% | 84 days | 136 days (Dec 18, 2023) |
| Mar 27, 2024 | Jun 6, 2024 | -23.3% | 49 days | 83 days (Oct 4, 2024) |
Declines of 10% or more from a closing high, measured on daily closes.
Financial statements
- Market cap
- $714.2M
- P/E (TTM)
- 17.8
- EPS, diluted (TTM)
- $1.24
- Revenue (TTM)
- $808.2M
- 52-week range
- $21.43 – $50.79
| FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|
| Revenue | $276.9M | $463.9M | $566.8M | $631.4M | $780.6M |
| Gross profit | $150.6M | $209.5M | $326.2M | $377.3M | $463.3M |
| Operating income | $17.6M | $33.3M | $167.0M | $169.9M | $187.1M |
| Net income | $71.5M | -$25.0M | $48.2M | $69.2M | $62.9M |
| EPS (diluted) | $1.86 | -$0.74 | $1.29 | $1.86 | $1.73 |
| Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | Q1 2026 | Q2 2026 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $159.3M | $181.9M | $177.8M | $188.0M | $209.4M | $205.4M | $193.5M | $199.9M |
| Net income | $9.3M | $12.5M | $2.4M | $12.0M | $31.5M | $17.0M | $14.5M | -$15.1M |
| EPS (diluted) | $0.27 | $0.35 | $0.07 | $0.34 | $0.84 | $0.46 | $0.40 | -$0.46 |
| FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|
| Operating cash flow | $103.6M | $124.2M | $274.7M | $205.0M | $329.3M |
| Capital expenditure | -$1.9M | -$1.6M | -$461,000 | -$1.7M | -$1.7M |
| Free cash flow | $101.6M | $122.6M | $274.3M | $203.3M | $327.6M |
| Dividends paid | $0 | $0 | $0 | $0 | $0 |
| Net share buybacks | -$47.9M | -$14.1M | -$75.0M | -$60.0M | -$19.5M |
Cash outflows are shown as negative numbers.
- Cash and short-term investments
- $129.5M
- Total assets
- $2.14B
- Total liabilities
- $1.82B
- Total debt
- $857.8M
- Net debt
- $728.3M
- Shareholders’ equity
- $311.9M
As of Jun 30, 2026 (filed Aug 6, 2026).
Short interest
- Shares sold short
- 5,675,115
- Days to cover
- 6.03
- Change vs previous report
- -6.4%
FINRA short interest, settlement date Sep 15, 2026.